FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800788397> ?p ?o ?g. }

• W2800788397 abstract "Abstract Background The efficacy and safety of recombinant Escherichia coli –asparaginase (rASNase) was compared to native E.coli asparaginase (Asparaginase medac). Methods One hundred and ninety‐nine children with newly diagnosed acute lymphoblastic leukemia were randomized to receive one of both agents at a dose of 5,000 U/m² during induction (eight doses) and 10,000 U/m² during the postinduction phase (only high‐risk patients; standard‐ and medium‐risk patients received pegaspargase). Results Median trough serum asparaginase activity levels were comparable between both groups; they ranged from 143 to 182 U/l during induction and were above the target value of 100 U/l. Complete asparagine depletion in serum was achieved in 97.9% of patients, with no significant differences between both groups. On day 33 (end of induction), only two (2%) evaluable patients in each group had measurable asparagine serum levels, and complete asparagine depletion in the cerebrospinal fluid was achieved in 98.8% and 93.6% of the patients with rASNase and Asparaginase medac, respectively. During induction, 2.1% and 5% of patients developed an allergic reaction to rASNase or Asparaginase medac, respectively. Approximately 41% of the patients in both groups had a clinical allergy or enzyme inactivation to the first dose of any asparaginase preparation in postinduction. A comparable proportion of patients in both groups developed anti‐asparaginase antibodies (57%) during repeated administration of asparaginase. Minimal residual disease levels at the end of induction, 5‐year event‐free survival, and 5‐year cumulative incidence of relapse did not differ between both groups. Conclusion The efficacy, safety, and immunogenicity of both asparaginase preparations are comparable. This trial was registered at www.clinicaltrials.gov as #NCT00784017; EudraCT number 2006‐003180‐31." @default.
• W2800788397 created "2018-05-17" @default.
• W2800788397 creator A5010920542 @default.
• W2800788397 creator A5017731507 @default.
• W2800788397 creator A5034780846 @default.
• W2800788397 creator A5035292815 @default.
• W2800788397 creator A5037151292 @default.
• W2800788397 creator A5043037950 @default.
• W2800788397 creator A5051953242 @default.
• W2800788397 creator A5051959181 @default.
• W2800788397 creator A5075070173 @default.
• W2800788397 creator A5076653129 @default.
• W2800788397 creator A5082616655 @default.
• W2800788397 creator A5084943918 @default.
• W2800788397 date "2018-05-04" @default.
• W2800788397 modified "2023-10-16" @default.
• W2800788397 title "Efficacy and safety of recombinant <i>E. coli</i> asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group" @default.
• W2800788397 cites W1598205549 @default.
• W2800788397 cites W1965542498 @default.
• W2800788397 cites W2005688611 @default.
• W2800788397 cites W2005725119 @default.
• W2800788397 cites W2013649602 @default.
• W2800788397 cites W2021422854 @default.
• W2800788397 cites W2050766351 @default.
• W2800788397 cites W2065158892 @default.
• W2800788397 cites W2065193985 @default.
• W2800788397 cites W2096489857 @default.
• W2800788397 cites W2134716997 @default.
• W2800788397 cites W2140819149 @default.
• W2800788397 cites W2162448677 @default.
• W2800788397 cites W2215516645 @default.
• W2800788397 cites W2292251821 @default.
• W2800788397 cites W2337036931 @default.
• W2800788397 cites W2413038045 @default.
• W2800788397 cites W2471256249 @default.
• W2800788397 cites W2474118332 @default.
• W2800788397 doi "https://doi.org/10.1002/pbc.27083" @default.
• W2800788397 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29727043" @default.
• W2800788397 hasPublicationYear "2018" @default.
• W2800788397 type Work @default.
• W2800788397 sameAs 2800788397 @default.
• W2800788397 citedByCount "17" @default.
• W2800788397 countsByYear W28007883972019 @default.
• W2800788397 countsByYear W28007883972020 @default.
• W2800788397 countsByYear W28007883972021 @default.
• W2800788397 countsByYear W28007883972022 @default.
• W2800788397 countsByYear W28007883972023 @default.
• W2800788397 crossrefType "journal-article" @default.
• W2800788397 hasAuthorship W2800788397A5010920542 @default.
• W2800788397 hasAuthorship W2800788397A5017731507 @default.
• W2800788397 hasAuthorship W2800788397A5034780846 @default.
• W2800788397 hasAuthorship W2800788397A5035292815 @default.
• W2800788397 hasAuthorship W2800788397A5037151292 @default.
• W2800788397 hasAuthorship W2800788397A5043037950 @default.
• W2800788397 hasAuthorship W2800788397A5051953242 @default.
• W2800788397 hasAuthorship W2800788397A5051959181 @default.
• W2800788397 hasAuthorship W2800788397A5075070173 @default.
• W2800788397 hasAuthorship W2800788397A5076653129 @default.
• W2800788397 hasAuthorship W2800788397A5082616655 @default.
• W2800788397 hasAuthorship W2800788397A5084943918 @default.
• W2800788397 hasConcept C120665830 @default.
• W2800788397 hasConcept C121332964 @default.
• W2800788397 hasConcept C126322002 @default.
• W2800788397 hasConcept C197934379 @default.
• W2800788397 hasConcept C2778461978 @default.
• W2800788397 hasConcept C2778904437 @default.
• W2800788397 hasConcept C2781107101 @default.
• W2800788397 hasConcept C2909962599 @default.
• W2800788397 hasConcept C61511704 @default.
• W2800788397 hasConcept C71924100 @default.
• W2800788397 hasConcept C72563966 @default.
• W2800788397 hasConcept C88879693 @default.
• W2800788397 hasConcept C90924648 @default.
• W2800788397 hasConceptScore W2800788397C120665830 @default.
• W2800788397 hasConceptScore W2800788397C121332964 @default.
• W2800788397 hasConceptScore W2800788397C126322002 @default.
• W2800788397 hasConceptScore W2800788397C197934379 @default.
• W2800788397 hasConceptScore W2800788397C2778461978 @default.
• W2800788397 hasConceptScore W2800788397C2778904437 @default.
• W2800788397 hasConceptScore W2800788397C2781107101 @default.
• W2800788397 hasConceptScore W2800788397C2909962599 @default.
• W2800788397 hasConceptScore W2800788397C61511704 @default.
• W2800788397 hasConceptScore W2800788397C71924100 @default.
• W2800788397 hasConceptScore W2800788397C72563966 @default.
• W2800788397 hasConceptScore W2800788397C88879693 @default.
• W2800788397 hasConceptScore W2800788397C90924648 @default.
• W2800788397 hasFunder F4320328692 @default.
• W2800788397 hasIssue "8" @default.
• W2800788397 hasLocation W28007883971 @default.
• W2800788397 hasLocation W28007883972 @default.
• W2800788397 hasOpenAccess W2800788397 @default.
• W2800788397 hasPrimaryLocation W28007883971 @default.
• W2800788397 hasRelatedWork W2055132182 @default.
• W2800788397 hasRelatedWork W2121951546 @default.
• W2800788397 hasRelatedWork W2127866346 @default.
• W2800788397 hasRelatedWork W2265868850 @default.
• W2800788397 hasRelatedWork W2403305186 @default.
• W2800788397 hasRelatedWork W2415666441 @default.
• W2800788397 hasRelatedWork W2784353927 @default.
• W2800788397 hasRelatedWork W2910921196 @default.

• next